Pituitary Research and Clinical Trials

IV Drips in various colors

The OHSU Pituitary Center has established a track record as a groundbreaking research program, linking resources from across specialty areas to further insight into the cause of pituitary conditions and to develop new treatments. With several past breakthroughs and several clinical trials currently underway, we are at the forefront of investigating pituitary conditions.

Clinical trials are the last step in a lengthy process of research. These studies allow scientists to test the value of their research to diagnose, treat and prevent diseases and disabilities. Each clinical trial is an opportunity to test a promising invention or treatment.

Our research studies are focused on the medical treatment of hyperfunctioning pituitary tumors, patient outcomes, quality of life, and pituitary dysfunction before and after surgical and/or other additional therapies for pituitary adenomas.

Currently, we are involved in more than a dozen active studies for pituitary disorders that include (but are not limited to) Cushing’s disease, acromegaly and growth hormone deficiency.

As the West Coast’s most comprehensive pituitary center and one of the largest in the country, we were a major contributor to clinical studies that resulted in two new FDA-approved, first-in-their-class treatments for Cushing’s disease and one for acromegaly (e.g., glucocorticoid receptor blockers and somatostatin receptor ligands). We are involved in many international pituitary clinical trials and frequently have the highest patient participation.

Please contact us for more information.

  1. Trial to Compare the Efficacy and Safety of NNC0195-0092 With Placebo and Norditropin® FlexPro® in Adults With Growth Hormone Deficiency (REAL 1)
    Condition: Adult Growth Hormone Deficiency
    Intervention: Drug: NNC0195-0092, Drug: somatropin, Drug: placebo
  2. Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
    Condition: Cushing's Disease
    Intervention: Drug: LCI699
  3. A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency
    Condition: Adult Growth Hormone Deficiency
    Intervention: Drug: MOD-4023
  4. Treatment for Endogenous Cushing's Syndrome
    Condition: Endogenous Cushing's Syndrome
    Intervention: Drug: COR-003

Make an appointment

Call 503-494-4314 

Toll-free 888-222-6478

Refer a patient